Northwest Biotherapeutics

Executive Summary

Northwest Biotherapeutics is a private biotechnology company focused on developing personalized immunotherapies for solid tumors, with a primary candidate DCVax-L (autologous dendritic cell vaccine) targeting glioblastoma (GBM). The company has been advancing DCVax-L through clinical trials, including a Phase 3 study in newly diagnosed GBM, for which enrollment was completed in 2022. Additionally, DCVax-Direct is being evaluated in multiple solid tumors via intratumoral injection. Despite years of development and mixed data interpretations, the company remains committed to regulatory approval pathways. Recent efforts have centered on data analysis from the Phase 3 trial of DCVax-L, with potential to support a Biologics License Application (BLA) filing. The company has also explored partnerships to expand manufacturing and commercialization capabilities. While financial disclosures are limited due to its private status, NW Bio continues to operate as a going concern, leveraging its proprietary dendritic cell technology. Upcoming milestones include final Phase 3 data presentation and any regulatory decisions from the FDA or other authorities.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 DCVax-L final data release or presentation60% success
• Q4 2026FDA meeting or regulatory submission for DCVax-L in GBM40% success
• Q3 2026Strategic partnership or licensing deal for DCVax platform50% success